The rising demand for GLP-1 medications — widely recognized for their effectiveness in weight management and chronic disease prevention — has created a significant coverage gap in Medicare. Historically, federal law has prohibited Medicare Part D from covering drugs prescribed solely for weight loss. The Medicare GLP-1 Bridge program represents Centers for Medicare & Medicaid Services (CMS)’s first major step toward addressing this gap.
For Medicare stakeholders, including beneficiaries, advisors, and plan sponsors, this short-term demonstration signals a meaningful shift in how high-cost, high-impact therapies may be integrated into the program moving forward.
The Medicare GLP-1 Bridge program is a CMS-led, short-term demonstration program launching July 1, 2026, and running through December 31, 2027. It is designed to provide eligible Medicare Part D beneficiaries access to select GLP-1 medications for weight management — a category traditionally excluded from coverage.
Importantly, the program functions outside the standard Medicare Part D benefit structure. CMS has established a centralized processing system that handles prior authorization, claims adjudication, and pharmacy payments, rather than relying on individual Part D plans.
The Bridge was originally designed as a transitional step toward the CMS BALANCE Model. However, CMS has since extended the Bridge program through December 31, 2027, while broader Medicare implementation of BALANCE remains under evaluation.
For Medicare beneficiaries, the GLP-1 Bridge program represents expanded access — but with important nuances. The Medicare GLP-1 Bridge program is intended for beneficiaries who are not already eligible for GLP-1 coverage through Part D. Those receiving GLP-1 medications for conditions such as diabetes, sleep apnea, or MASH typically remain covered through their existing Medicare drug plan.
Eligible beneficiaries can access certain GLP-1 drugs — such as Wegovy, Zepbound, and Foundayo tablets — specifically for weight management, even though these are not typically covered under Part D. Not all GLP-1 products qualify.
To qualify for GLP-1 eligible beneficiaries must:
The GLP-1 Bridge program offers a flat monthly copay of $50, regardless of benefit phase.
However, there are important trade-offs:
For some beneficiaries — particularly those on fixed incomes — these limitations may affect affordability despite the relatively low flat copay.
Beneficiaries will interact with a different administrative system than their standard Part D plan for these medications. This includes:
This separation may introduce confusion without proper education and guidance.
The GLP-1 Bridge program also has significant implications for Part D plan sponsors — particularly in terms of risk, compliance, and future strategy.
Because the program operates outside Part D:
This design allows CMS to test expanded access without immediately impacting plan premiums or benefit structures.
Part D plans must still:
Plans cannot restrict access or steer beneficiaries toward the Bridge program inappropriately.
While plans are not directly involved in administering the Bridge, they must:
The program also offers CMS an opportunity to collect utilization and cost data, which could influence long-term Part D design and pricing strategies.
The GLP-1 Bridge program represents more than a temporary coverage solution — it reflects a broader shift in how Medicare may approach high-cost, high-demand therapies.
GLP-1 medications have already driven substantial spending growth in Medicare, highlighting both their clinical impact and financial complexity.
By carving out a separate demonstration:
The program’s temporary status raises important questions:
For Medicare stakeholders, the GLP-1 Bridge program is a pivotal development at the intersection of clinical innovation and policy evolution. It expands access in the near term while laying the groundwork for potential long-term change.
As Medicare continues to evolve, programs like the GLP-1 Bridge highlight a central challenge: balancing access, affordability, and sustainability in an era of rapidly advancing therapies.
If you have questions about how the CMS GLP-1 Bridge program may affect your Medicare coverage or would like guidance evaluating your options, connect with a Brown & Brown Medicare specialist.
Brenda Shearer is the National Director of EB Select and Medicare, dedicated to providing day-to-day employee benefit account management for customers and brokers, as well as the management of the staff. She has extensive training and knowledge of all major carriers in the marketplace, including individual, Medicare, small and large group products. She has also worked closely with large accounts and PEO’s.
Brown & Brown does not offer every plan available in every geographic location. Any information Brown & Brown provides is limited to those plans offered by Brown & Brown. Brown & Brown is not connected nor endorsed by the United States or any state government or Medicare program. Please contact Medicare.gov or 1-800-Medicare to get information on all your options.